Hepatitis B Annual

Current Issue  

Back Issues   


Search Login    Users online: 323 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
>>> Ahead of Print <<<
Year : 2009  |  Volume : 6  |  Issue : 1  |  Page : 41-54

Tenofovir for HBV: The beginning of the end or the end of the beginning?

Department of Gastroenterology and Liver Diseases, Columbia Asia Referral Hospital, Bangalore - 560 055, India

Correspondence Address:
Naresh Bhat
Department of Gastroenterology and Liver Diseases, Columbia Asia Referral Hospital, Yeshwanthpur, Dr. Rajkumar Road, Malleshwaram West, Bangalore - 560 055
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0972-9747.76904

Rights and Permissions

Patients with Hepatitis B virus infection may present to the treating clinicians at various stages of natural history of hepatitis B infection, including acute viral hepatitis, chronic active hepatitis, incidental hepatitis B s antigen-positive patients and those with decompensated cirrhosis and hepatocellular carcinoma. Management of chronic hepatitis B patients, especially those with e antigen-negative disease poses the biggest challenge today. There are various treatment options available and choosing the correct drug according to the patient profile is important both for optimum response and preventing drug resistance. This article reviews an exciting new molecule tenofovir, which has been approved in August 2008 by the US Food and Drug Administration for treatment of chronic hepatitis B.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded481    
    Comments [Add]    

Recommend this journal